Evoke Pharma, a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, has selected the Patheon division of Thermo Fisher Scientific as the commercial manufacturing partner for Gimoti, Evoke’s nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Thermo Fisher is a global contract development and manufacturing organization (CDMO) with specialized capabilities for the preparation, fill and finish of nasal spray products. Under the five-year agreement, Thermo Fisher will manufacture Gimoti for Evoke’s potential commercial efforts.

“We are very pleased to announce the selection of Thermo Fisher as our commercial manufacturing partner, which will supply Gimoti in accordance with FDA standards for chemistry, manufacturing and controls (CMC) as we move closer toward a potential approval of Gimoti,” said Dave Gonyer, president and chief executive officer, Evoke. “We believe that Thermo Fisher’s recent acquisition of Patheon, a CDMO who we have worked closely with since 2008, provides additional expertise in the manufacturing of nasal spray products and makes them an ideal partner. The partnership is another critical step for the company as we continue to move closer to the commercialization of Gimoti and we are working diligently to prepare and finalize our NDA submission by next quarter.”